FocalTherics (FOCL) Projected to Announce Quarterly Earnings on Thursday

Key Points

• FocalTherics is expected to report Q2 2026 results before market open on August 27. Analysts forecast a loss of $0.2287 per share and revenue of approximately $22.5 million.
• The company’s previous quarter fell short of expectations, reporting a $0.39 per-share loss versus the $0.20 consensus estimate, with revenue of $13.2 million. FocalTherics remains unprofitable, with a negative net margin of 56.26%.
• Analyst sentiment is mixed, with an overall “Hold” rating and a consensus price target of $7.75 compared with the stock’s $4.36 opening price. Insiders have purchased 116,000 shares worth about $551,000 over the past 90 days.

FocalTherics (NASDAQ:FOCL - Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 27th. Analysts expect the company to announce earnings of ($0.2287) per share and revenue of $22.4840 million for the quarter. Investors may visit the the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

FocalTherics (NASDAQ:FOCL - Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The business had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%. On average, analysts expect FocalTherics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

FocalTherics Price Performance

NASDAQ FOCL opened at $4.36 on Thursday. The stock's 50 day simple moving average is $5.37. FocalTherics has a one year low of $1.30 and a one year high of $6.40. The company has a market cap of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.60.

Analysts Set New Price Targets

A number of equities analysts have commented on FOCL shares. Piper Sandler reissued a "neutral" rating and issued a $4.00 price objective on shares of FocalTherics in a research note on Friday, August 14th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. Mizuho set a $15.00 price target on FocalTherics and gave the company an "outperform" rating in a report on Friday, July 17th. Wall Street Zen downgraded shares of FocalTherics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of FocalTherics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, FocalTherics has an average rating of "Hold" and a consensus target price of $7.75.

Insider Transactions at FocalTherics

In related news, Director David R. Horn acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the transaction, the director directly owned 10,000 shares of the company's stock, valued at approximately $47,500. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Fran Schulz acquired 10,000 shares of FocalTherics stock in a transaction on Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the director owned 15,100 shares in the company, valued at approximately $71,725. This represents a 196.08% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 116,000 shares of company stock worth $551,000 over the last ninety days. 10.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On FocalTherics

An institutional investor recently bought a new position in FocalTherics stock. Kovack Advisors Inc. purchased a new stake in FocalTherics (NASDAQ:FOCL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 16,000 shares of the company's stock, valued at approximately $53,000. Institutional investors own 62.74% of the company's stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source